Timely recognition of the signs and symptoms of posterior circulation stroke (PCS) is critical for properly diagnosing PCS, understanding the clinical course, and managing patients with acute PCS diagnosis. Delayed or incorrect diagnosis results in inadequate acute care and poorer outcomes. While PCS can be challenging to recognize; in this webinar series learn to distinguish characteristic clinical patterns and apply AHA/ACC guideline recommendations.
Join a Webinar Series – Available On-Demand
HCM Webinar Series @Model.Item.RenderHeadingSizeTag("h2")>
With your help, patients whose lives have been restricted due to HCM may be able to reduce symptoms and comorbidities. Register today and increase your knowledge of the latest HCM science.
ATTR Amyloidosis Webinar Series @Model.Item.RenderHeadingSizeTag("h2")>
Amyloidoses are a heterogeneous group of systemic disorders characterized by extra cellular deposition of a protein-derived material (known as amyloid) that disrupts normal tissue structure and function. Improve the care of patients with Transthyretin Amyloidosis (ATTR amyloidosis) by closing practice and knowledge gaps in disease presentation as experts discuss the complexities of this progressive, degenerative, and multisystemic disorder.
An Overview of 2020 ACC/AHA Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy @Model.Item.RenderHeadingSizeTag("h2")>
A discussion of key take-aways following the release of the 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy. Viewers learn through early symptom recognition, diagnosis, treatment, and engagement with patients, healthcare professionals can improve the management of hypertrophic cardiomyopathy (HCM).
Posterior Circulation Stroke Webinar Series
Secondary Stroke Prevention: Evidence-based Recommendations
Join Drs. Broderick, Kleindorfer, and Towfighi as they identify the implications for clinicians in the 2021 Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack. With your help through prevention strategies, patients with ischemic stroke/transient ischemic attack may experience improved outcomes and quality of life.
Moderator: Joseph P. Broderick, MD, FAHA
Professor of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine
Director, University of Cincinnati Gardner Neuroscience Institute
Presenter: Dawn Kleindorfer, MD, FAHA
Writing Group Chair
Chair and Professor of Neurology, University of Michigan
Presenter: Amytis Towfighi, MD, FAHA
Writing Group Vice Chair
Chief of Neurology, Associate Medical Director of Neurological Services, and Director of Research, LAC+USC Medical Center
Director, Neurological Services, Los Angeles County Department of Health Services
Associate Professor of Neurology (Clinical Scholar), USC Keck School of Medicine
Co-Director of Research and Director of Implementation Science, SC Clinical and Translational Science Institute
Sudden Cardiac Death Prevention in HCM: Where Do We Stand in 2021?
Presenters: Martin S. Maron, MD; Marye Gleva, MD
Moderator: James E. Udelson, MD, FAHA
Some people with HCM are at increased risk for developing atrial fibrillation, heart failure, suffering from stroke and even sudden cardiac death (SCD). Patients who suffer from arrhythmias associated with HCM may require implantable cardioverter-defibrillator devices to reduce their risk of SCD. Join Drs. Maron, Gleva, and Udelson as they discuss risk stratification strategies, device selection, and the role of shared decision-making in the prevention of SCD.
Dr. James E. Udelson, MD, FAHA
Chief, Division of Cardiology,
Tufts Medical Center
Martin S. Maron, MD
Director of the Hypertrophic Cardiomyopathy Center and the Co-Director of the Cardiac CT and MRI program at Tufts Medical Center and Associate Professor at Tufts University School of Medicine
Marye Gleva, MD
Professor of Medicine, Washington University School of Medicine in St. Louis
Ethics and Professionalism: A Common Ground of Understanding
Ethics and professionalism in science and medicine are central in addressing contemporary issues. In this current climate how are we to respond to unprecedented public challenges, including the physical and economic health of the country, tragedies of social justice, and a divisive political climate?
Join former AHA Presidents Dr. Bob Harrington and Dr. Ivor Benjamin along with other thought leaders for an engaging roundtable conversation in regards to the 2021 AHA/ACC Ethics and Professionalism Report.
Building on the AHA’s long history of leadership in the areas of medical ethics and professionalism, this roundtable discussion will include reflections on specific issues such as:
- shared clinical decision-making
- the relationship of clinicians with patients, other clinicians, and organizations
- allocation of resources
- scientific responsibility and integrity in research
|Dr. Bob Harrington||Dr. Ivor Benjamin|
W.O.W. Why hOw and When to measure Lipoprotein(a): A Clinically Relevant Cardiovascular Risk Factor
Do you know the principles of why, how and when to consider measuring Lp(a) levels in your patients? Drs. Kamstrup, Soffer and Yeang will describe the latest scientific evidence and support the ongoing guidelines and methods being used in the field. You will better understand the risk factors associated with high levels of Lp(a) and the available methods to measure its levels. Register and learn the limitations of the available assays and recommendations for best use practices, risk, independent of assay used. Reserve your place today!
Supported by an educational grant from Kaneka Corporation.
Moderator: Bart Duell, MD
Professor of Medicine,
Division of Cardiovascular Medicine,
School of Medicine, Oregon Science & Health University
Presenter: Pia Kamstrup, MD, PhD
Head of Dept of Clinical Biochemistry,
Herlev and Gentofte Hospital,
Copenhagen University Hospital, Denmark
Presenter: Gissette Reyes-Soffer, MD
Herbert Irving Assistant Professor of Medicine
Columbia University Medical Center,
College of Physicians and Surgeons
Presenter: Calvin Yeang, MD, PhD
UC San Diego Heath
Lipoprotein(a): The Science Behind the Risk Factor
Elevated Lp(a) is associated with increased risk of MI and stroke, among other conditions.1
As a clinician, do you know the role Lp(a) plays in dyslipidemia and adverse events? Join Drs. Koschinsky, Kronenberg, and Toth as they explore the structure of Lp(a) and how this is related to assessment of plasma Lp(a) levels. Register today to learn the latest thinking on how LPA gene encoding apo(a) impacts plasma Lp(a) levels in your patients. CE Credit eligible.
1Likozar AR, Zavrtanik M, Sebestjen M. Lipoprotein(a) in atherosclerosis: From pathophysiology to clinical relevance and treatment options. Ann Med. 2020;52(5):162-177.
Key Implications for Clinicians in the 2020 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease
In your evaluation of a patients with suspected valvular heart disease, learn the diagnostic strategies for early detection of valvular disease and appropriate long term management. Discover appropriate tools for assessment and intervention based on valvular disease stage, specifically in cases of mitral regurgitation and aortic stenosis.
These are some of the areas identified in the new guideline on managing patients with valvular heart disease. Thoralf Sundt, MD, Vera Rigolin, MD, and Hani Jneid, MD explore guideline updates and explain how revised recommendations translate into clinical practice.